During updated strategic framework to optimize the value of our MS business while investing for the future across our core growth areas of MS and neuroimmunology, Alzheimer’s disease and dementia, movement disorders and neuromuscular diseases, including SMA and amyotrophic lateral sclerosis (ALS).